BlossomHill director tied to OrbiMed IPO stake
BlossomHill Therapeutics, Inc. (BLSM) had director Carl L. Gordon file an initial statement of beneficial ownership.
Rhea-AI Filing Summary
BlossomHill Therapeutics, Inc. (BLSM) had director Carl L. Gordon file an initial statement of beneficial ownership. The filing reports indirect holdings, through OrbiMed Private Investments VIII, LP, of Series A Preferred Stock and Series B Preferred Stock, together convertible into common stock on a 1-for-1 basis upon the closing of the company’s initial public offering, with no expiration date. Control and voting power over these securities are described as residing with OrbiMed entities, and members of the OrbiMed management committee, including Gordon, each disclaim beneficial ownership of the shares held by OrbiMed Private Investments VIII, LP.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
GORDON CARL L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock F1, F2 | -- | -- | -- |
| holding | Series B Preferred Stock F1, F2 | -- | -- | -- |
Holdings After Transaction:
Series A Preferred Stock — 1,039,996 contracts (Indirect, By OrbiMed Private Investments VIII, LP);
Series B Preferred Stock — 1,049,283 contracts (Indirect, By OrbiMed Private Investments VIII, LP)
Footnotes (2)
- F1. Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") is convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock has no expiration date.
- F2. The shares are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
Key Figures
Underlying common shares from Series A Preferred Stock: 1,039,996 shares
Underlying common shares from Series B Preferred Stock: 1,049,283 shares
Conversion ratio: 1 share of Preferred Stock for 1 share of Common Stock
3 metrics
Underlying common shares from Series A Preferred Stock
1,039,996 shares
Shares of common stock underlying Series A Preferred Stock held indirectly through OrbiMed Private Investments VIII, LP
Underlying common shares from Series B Preferred Stock
1,049,283 shares
Shares of common stock underlying Series B Preferred Stock held indirectly through OrbiMed Private Investments VIII, LP
Conversion ratio
1 share of Preferred Stock for 1 share of Common Stock
Each share of Series A and Series B Preferred Stock converts into one share of common stock upon IPO closing
Key Terms
beneficial ownership, Preferred Stock, initial public offering, indirect, +1 more
5 terms
beneficial ownership financial
"may be deemed to have beneficial ownership over such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Preferred Stock financial
"Each share of Series A Preferred Stock and Series B Preferred Stock"
Preferred stock is a type of ownership in a company that typically offers investors higher and more consistent dividend payments than common stock. Unlike regular shares, preferred stock usually doesn’t come with voting rights but provides a priority claim on the company’s assets and profits, making it a more stable and predictable investment option. This makes preferred stock attractive to those seeking steady income with lower risk.
initial public offering financial
"convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
indirect financial
"The shares are held directly by OrbiMed Private Investments VIII, LP"
management committee financial
"OrbiMed Advisors exercises voting and investment power through a management committee"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing disclose about BLSM director Carl L. Gordon’s holdings?
It discloses that Carl L. Gordon has indirect beneficial ownership of BlossomHill Therapeutics securities held by OrbiMed Private Investments VIII, LP, consisting of Series A and Series B Preferred Stock that are convertible into common stock upon the company’s initial public offering.
AI-generated analysis. How Rhea-AI works. Not financial advice.
